

- 47 -

We claim:

1. A method of treating metastatic tumors in a subject, which method comprises:  
5 administering to a subject afflicted by metastatic tumors effective amounts of a photosensitizer and an immuno-adjuvant, and  
irradiating said subject with light absorbed by said photosensitizer,  
wherein said method is photochemical mediated photodynamic therapy (PDT).

2. A method of preventing or inhibiting the development of metastatic tumors in a subject, which method comprises:  
administering to a subject at risk for developing metastatic tumors effective amounts of a photosensitizer and an immuno-adjuvant, and  
15 irradiating said subject with light absorbed by the photosensitizer.

3. A method of treating a primary tumor in a subject, which method comprises:  
administering to a subject clinically diagnosed with a primary tumor effective amounts of a photosensitizer and an immuno-adjuvant, and  
20 irradiating said subject with light absorbed by said photosensitizer.

4. The method of claim 2 wherein said subject has previously undergone cancer or tumor therapy.

5. The method of claims 1, 2 or 3 wherein said effective amount of a photosensitizer is in the range of 0.05 to 10 mg/kg.

- 48 -

Sub  
C2

6. The method of claim 5 wherein said effective amount of a photosensitizer is in the range of 0.05 to 1 mg/kg.

7. The method of claim 5 wherein said effective amount of a photosensitizer is in the range of 1 to 10 mg/kg.

8. The method of claims 1 or 3 wherein said photosensitizer is administered intravenously and said immuno-adjuvant is administered by injection into tumors.

10 9. The method of claims 1 or 3 wherein said irradiation is localized to the tumors.

10. The method of claim 2 wherein said photosensitizer is administered intravenously or intratumorally.

15 11. The method of claims 1, 2 or 3 wherein said photosensitizer is administered, and the subject irradiated, before administration of the immuno-adjuvant.

12. The method of claims 1, 2 or 3 wherein said immuno-adjuvant is administered systemically.

20 13. The method of claims 1, 2 or 3 wherein the photosensitizer is a benzoporphyrin derivative (BPD) or a green porphyrin.

25 14. The method of claim 13 wherein the BPD is BPD-MA, EA6, or B3.

- 49 -

5b  
2  
D  
15. The method of claims 1, 2 or 3 further comprising an additional irradiation, before irradiation with light absorbed by the photosensitizer, with light of a wavelength which improves penetration of the absorbed light.

16. The method of claim 1 wherein said immuno-adjuvant comprises mycobacterial cell wall skeletons and de-3-O-acylated lipid A.

17. A pharmaceutical composition to treat, prevent, or inhibit the development of, metastatic tumors, said composition comprising:

10 a photosensitizer and an immuno-adjuvant in amounts effective to treat, prevent, or inhibit the development of, metastatic tumors, and  
a pharmaceutically acceptable carrier or excipient.

18. The composition of claim 17 wherein the photosensitizer is a BPD or a  
15 green porphyrin.

19. The composition of claim 18 which is a liposomal formulation.

20. The composition of claim 18 wherein the BPD is BPD-MA, EA6, or B3.

21. The composition of claim 18 wherein said immuno-adjuvant comprises mycobacterial cell wall skeletons and de-3-O-acylated lipid A.